Current trials and novel therapeutic targets for alcoholic hepatitis

Ashwani K. Singal, Vijay Shah

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Alcoholic hepatitis is a clinical syndrome in which patients present with acute-on-chronic liver failure and a high risk of short-term mortality. The current treatment of alcoholic hepatitis is suboptimal. Results recently published from the STOPAH study have improved our understanding of how best to design clinical trials for this condition. Although emerging data on liver transplantation for patients with alcoholic hepatitis are encouraging, less than 2% of these patients qualify. Clearly, there is an unmet need for novel treatments to improve the survival of these patients. Changes in the gut microbiota, inflammatory and cytokine signalling, oxidative stress and mitochondrial dysfunction, and abnormalities in the hepatic regenerative capacity alone or in combination contribute to the pathology of alcoholic hepatitis. In this chapter, we will describe the novel therapeutic agents targeting various pathways in the pathophysiology of alcoholic hepatitis. Specifically, we will describe the ongoing clinical trials in which some of these agents are being studied.

Original languageEnglish (US)
JournalJournal of Hepatology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Alcoholic Hepatitis
Clinical Trials
Therapeutics
Liver Transplantation
Oxidative Stress
Pathology
Cytokines
Survival
Mortality
Liver

Keywords

  • ALD
  • Corticosteroids
  • STOPAH, Therapeutic

ASJC Scopus subject areas

  • Hepatology

Cite this

Current trials and novel therapeutic targets for alcoholic hepatitis. / Singal, Ashwani K.; Shah, Vijay.

In: Journal of Hepatology, 01.01.2018.

Research output: Contribution to journalArticle

@article{9b0f6b78f2a14e97a07eac3d8e3917d4,
title = "Current trials and novel therapeutic targets for alcoholic hepatitis",
abstract = "Alcoholic hepatitis is a clinical syndrome in which patients present with acute-on-chronic liver failure and a high risk of short-term mortality. The current treatment of alcoholic hepatitis is suboptimal. Results recently published from the STOPAH study have improved our understanding of how best to design clinical trials for this condition. Although emerging data on liver transplantation for patients with alcoholic hepatitis are encouraging, less than 2{\%} of these patients qualify. Clearly, there is an unmet need for novel treatments to improve the survival of these patients. Changes in the gut microbiota, inflammatory and cytokine signalling, oxidative stress and mitochondrial dysfunction, and abnormalities in the hepatic regenerative capacity alone or in combination contribute to the pathology of alcoholic hepatitis. In this chapter, we will describe the novel therapeutic agents targeting various pathways in the pathophysiology of alcoholic hepatitis. Specifically, we will describe the ongoing clinical trials in which some of these agents are being studied.",
keywords = "ALD, Corticosteroids, STOPAH, Therapeutic",
author = "Singal, {Ashwani K.} and Vijay Shah",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jhep.2018.10.026",
language = "English (US)",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",

}

TY - JOUR

T1 - Current trials and novel therapeutic targets for alcoholic hepatitis

AU - Singal, Ashwani K.

AU - Shah, Vijay

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Alcoholic hepatitis is a clinical syndrome in which patients present with acute-on-chronic liver failure and a high risk of short-term mortality. The current treatment of alcoholic hepatitis is suboptimal. Results recently published from the STOPAH study have improved our understanding of how best to design clinical trials for this condition. Although emerging data on liver transplantation for patients with alcoholic hepatitis are encouraging, less than 2% of these patients qualify. Clearly, there is an unmet need for novel treatments to improve the survival of these patients. Changes in the gut microbiota, inflammatory and cytokine signalling, oxidative stress and mitochondrial dysfunction, and abnormalities in the hepatic regenerative capacity alone or in combination contribute to the pathology of alcoholic hepatitis. In this chapter, we will describe the novel therapeutic agents targeting various pathways in the pathophysiology of alcoholic hepatitis. Specifically, we will describe the ongoing clinical trials in which some of these agents are being studied.

AB - Alcoholic hepatitis is a clinical syndrome in which patients present with acute-on-chronic liver failure and a high risk of short-term mortality. The current treatment of alcoholic hepatitis is suboptimal. Results recently published from the STOPAH study have improved our understanding of how best to design clinical trials for this condition. Although emerging data on liver transplantation for patients with alcoholic hepatitis are encouraging, less than 2% of these patients qualify. Clearly, there is an unmet need for novel treatments to improve the survival of these patients. Changes in the gut microbiota, inflammatory and cytokine signalling, oxidative stress and mitochondrial dysfunction, and abnormalities in the hepatic regenerative capacity alone or in combination contribute to the pathology of alcoholic hepatitis. In this chapter, we will describe the novel therapeutic agents targeting various pathways in the pathophysiology of alcoholic hepatitis. Specifically, we will describe the ongoing clinical trials in which some of these agents are being studied.

KW - ALD

KW - Corticosteroids

KW - STOPAH, Therapeutic

UR - http://www.scopus.com/inward/record.url?scp=85057003352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057003352&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2018.10.026

DO - 10.1016/j.jhep.2018.10.026

M3 - Article

C2 - 30658731

AN - SCOPUS:85057003352

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

ER -